Living with LGI1 encephalitis: a study on long-term symptoms
Part of Brain & nervous system, Mental health clinical trials.
This study looks at symptoms, biomarkers, and mechanisms of the chronic phase of LGI1 antibody-mediated encephalitis. It aims to understand what happens after the acute stage and how to better manage long-term effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with LGI1 antibody-mediated encephalitis.
- You are past the acute (early) stage of the disease.
- You have been discharged from the hospital after the acute phase.
- You are able to give informed consent.
- You are able to travel to the study center for visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people newly diagnosed with anti-LGI1 encephalitis (a brain inflammation) to see how well they do over time. It aims to learn more about the condition and improve care.
This study follows patients with autoimmune encephalitis (brain inflammation caused by the immune system) to see how treatments affect them in the medium term. It may help doctors learn which treatments work best for people with this condition.
This study follows patients with chronic viral infections affecting the brain and spinal cord. Researchers will collect spinal fluid samples and track your health over one year to better understand these infections and improve care.
This research study looks for new markers in the blood of people with autoimmune encephalitis (a condition where the immune system attacks the brain). It aims to better understand what causes the disease and find new ways to diagnose it.
This study collects health information from people with autoimmune encephalitis, a condition where the body's immune system attacks the brain. It aims to understand the disease better, and if you have seizures from it, you can join a special epilepsy part.
This study looks at the long-term effects of the Alzheimer's drug LEQEMBI (lecanemab) in people with mild memory problems or early Alzheimer's. It gathers information from patients who have already been taking the drug for 18 months to see how they are doing.
Hear when a new Limbic Encephalitis With LGI1 Antibodies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.